Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

David Ziebarth

Pediatrics Cordova, TN Medical Doctor

NPI 1265532097 CMS profile 239147

1172 Vickery Ln, Cordova, TN 38016

Open in the dashboard

General payments

$3,353

284 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, David Ziebarth of Cordova, TN is reported in the CMS Open Payments database as having received $3,353 across 284 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $484 53
2022 General $533 52
2021 General $629 58
2020 General $878 54
2019 General $827 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Ziebarth
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to David Ziebarth were reported at $0. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year David Ziebarth Pediatrics median Middle half National median
2019 $827 $86 $31–$183 $163
2020 $878 $49 $22–$110 $114
2021 $629 $68 $27–$158 $132
2022 $533 $77 $30–$173 $149
2023 $484 $88 $33–$190 $160
2024 $0 $94 $34–$206 $164
2025 $0 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Tris Pharma Inc $1,544 181 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $294 14 payments
  3. GlaxoSmithKline, LLC. $265 12 payments
  4. Pfizer Inc. $236 14 payments
  5. Arbor Pharmaceuticals, Inc. $186 15 payments
  6. Adlon Therapeutics L.P. $181 9 payments
  7. Merck Sharp & Dohme Corporation $165 10 payments
  8. Ironshore Pharmaceuticals Inc. $148 8 payments
  9. Neos Therapeutics, LP $134 9 payments
  10. Shire North American Group Inc $67 4 payments
  11. Other $133 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,353 284 payments
Products named General payments · program years 2019–2023
  1. Dyanavel XR Adhd $782 65 payments
  2. Quillivant $424 31 payments
  3. VYVANSE $360 18 payments
  4. Dyanavel XR Adhd $320 59 payments
  5. Quillichew ER $304 17 payments
  6. BEXSERO $265 12 payments
  7. ADHANSIA XR $181 9 payments
  8. EUCRISA $175 10 payments
  9. GARDASIL 9 $152 9 payments
  10. Quillivant XR $142 11 payments
  11. Other $1,469 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record